Avecho Biotechnology Limited
Research Avecho Biotechnology Limited (OEZ) on Bullrun: market cap EUR 27.05M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOEZ
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 27.05M
- Financial periodFY2025
- RevenueAUD 1.25M
- Revenue growth-3.8%
- Net income-AUD 4.42M
- Free cash flowAUD 1.10M
- Gross margin71.9%
Valuation Snapshot
latest market cap is EUR 27.05M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 1.25M | -AUD 4.42M | AUD 1.10M | 71.9% | 0 | AUD 4.66M | AUD 14.47K | AUD 1.56M |
| FY2024 | AUD 1.29M | -AUD 3.12M | -AUD 3.97M | 64.4% | 0 | AUD 2.37M | AUD 1.08M | AUD 3.27M |
| FY2023 | AUD 473.55K | -AUD 3.44M | -AUD 3.18M | -9.2% | 0 | AUD 5.52M | AUD 175.15K | AUD 6.38M |
| FY2022 | AUD 1.21M | -AUD 2.34M | -AUD 1.72M | 72.1% | 0 | AUD 1.55M | AUD 246.08K | AUD 2.45M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 27.05M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Avecho Biotechnology Limited's market cap?
Avecho Biotechnology Limited's market capitalization is EUR 27.05M.
What does Avecho Biotechnology Limited do?
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches.